Status:
UNKNOWN
Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results.
Lead Sponsor:
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Conditions:
Mantle Cell Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
This is a multicentric, observational and retrospective study of the use of lenalidomide in patients with relapsed or refractory mantle cell lymphoma that are included in the RRMCL spanish program. T...
Eligibility Criteria
Inclusion
- ≥ 18 years old.
- Diagnosed with relapsed or refractory mantle cell lymphoma verified by a tissue biopsy.
- Treated with monotherapy or combination of lenalidomide.
- Not candidate for any of the therapeutic options approved until that date for this disease.
- Not candidate or unable to be included in any clinical trial due to availability or geographical difficulty.
- Registered in the RRMCL spanish program.
Exclusion
- ECOG \> 2.
- Patients with uncontrolled comorbidities.
- Blastoid variant.
- Central nervous system tumor infiltration.
- HIV, HBV and/or HCV active infection.
- Radiotherapy concomitant treatment or that have received radiotherapy in the previous 30 days to the beginning of the first cycle of lenalidomide.
- Diagnosed with other active solid tumor except for basal cell carcinoma skin cancer.
- Patients that haven´t completed at least one complete cycle of the treatment.
Key Trial Info
Start Date :
September 15 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 15 2020
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT04109872
Start Date
September 15 2018
End Date
July 15 2020
Last Update
February 5 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitario Virgen Macarena
Seville, Spain, 41009